PTC Therapeutics Inc

NASDAQ:PTCT  
40.17
+0.06 (+0.15%)
Products

FDA Approves Label Extension For Evrysdi For Infants With Spinal Muscular Atrophy Under 2 Months Old

Published: 05/31/2022 05:08 GMT
PTC Therapeutics Inc (PTCT) - FDA Approves Label Extension for Evrysdi® for Infants With Spinal Muscular Atrophy Under 2 Months Old.
Says Approval is Based on Interim Efficacy and Safety Data From Rainbowfish Study in Newborns.